| Quantity | 1 mg, 5 mg, 10 mg | 5 mg, 10 mg | 500 µ, g, 1 mg, 5 mg, 10 mg | 500 µ, g, 1 mg, 5 mg | 5 mg, 10 mg, 25 mg, 50 mg, 100 mg |
| Description | RSM3 TFA, a stapled peptide, is a METTL3-METTL14 inhibitor with an Kd of 3.10 µM. RSM3 TFA inhibits tumor growth while induces cell apoptosis. RSM3 TFA can be used for study of cancer[1] | Gap 26 TFA is a connexin mimetic peptide, composed of residue numbers 63-75 of the first extracellular loop of connexin 43 (gap junction blocker), containing the SHVR amino acid motif[1] | GLP-1(7-36), amide TFA is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells[1] | Histatin 5 TFA inhibits the activity of the host matrix metalloproteinases MMP-2 and MMP-9 with IC50s of 0.57 and 0.25 µM, respectively | Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake[1]... Read More |